Zydus receives Orphan Drug Designation from US FDA for malaria treatment
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US.
December 17, 2021
by expresspharma
Zydus announces completion of Phase-I trials of ZY19489
Zydus Cadila announced that its anti-malarial compound ZY19489 (MMV253) in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has now completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101].
February 5, 2021
by expresspharma
GSK, MMV filing for Kozenis in paediatric populations with P. vivax malaria accepted by Australian TGA
GSK and Medicines for Malaria Venture (MMV) announced today that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the indication of single-dose Kozenis (tafenoquine) to paediatric ...
January 14, 2021
by pharmaceutical-business-review
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV).
March 5, 2020
by worldpharmanews
EDCTP commits €21.9m to MMV-led malaria research consortium
The European and Developing Countries Clinical Trials Partnership (EDCTP) has granted €21.9m to the PAMAfrica research consortium.
March 4, 2020
by pharmaceutical-technology
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria
The goal of VivAccess is to support introduction and increased access to the suite of radical cure products to address these challenges
April 23, 2019
by biospectrumasia